Synergistic Immunity Induction System Against SARS-CoV-2

Publication ID: 24-11857620_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Immunity Induction System Against SARS-CoV-2,” Published Technical Disclosure No. 24-11857620_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857620_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,620.

Summary of the Inventive Concept

A novel system combining a replication-defective adenovirus-based vaccine with distinct technologies such as AI, IoT, blockchain, and novel materials to induce robust immunity against SARS-CoV-2, enhancing vaccine efficacy and monitoring capabilities.

Background and Problem Solved

The original patent disclosed a method of inducing immunity against SARS-CoV-2 using spike (S) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus. However, the patent's limitations include the lack of integration with other technologies to enhance vaccine efficacy and monitoring. The new inventive concept addresses these limitations by synergistically combining the adenovirus-based vaccine with AI, IoT, blockchain, and novel materials to create a more powerful system.

Detailed Description of the Inventive Concept

The new inventive concept comprises a replication-defective adenovirus encoding a CoV2 nucleocapsid protein fused to an endosomal targeting sequence (N-ETSD) and a CoV2 spike protein sequence optimized for cell surface expression. This adenovirus is administered in combination with an artificial intelligence-powered diagnostic tool for detecting SARS-CoV-2 infection, a blockchain-based tracking system for monitoring vaccine distribution and administration, and an IoT-enabled sensor for detecting SARS-CoV-2 antigens in a patient's bodily fluids. The system can also be formulated with novel materials having enhanced immunogenic properties. The adenovirus-based vaccine induces robust immunity against SARS-CoV-2, while the integrated technologies enhance vaccine efficacy, monitoring, and distribution.

Novelty and Inventive Step

The new claims introduce the concept of synergistically combining the adenovirus-based vaccine with AI, IoT, blockchain, and novel materials, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for inducing immunity against SARS-CoV-2.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different AI-powered diagnostic tools, blockchain-based tracking systems, or IoT-enabled sensors. Variations could also include formulating the vaccine composition with different novel materials or using distinct adenovirus-based vaccine constructs.

Potential Commercial Applications and Market

The synergistic immunity induction system against SARS-CoV-2 has significant commercial potential in the vaccine industry, particularly in the context of pandemic preparedness and response. The system's ability to enhance vaccine efficacy, monitoring, and distribution could lead to widespread adoption in healthcare systems globally.

CPC Classifications

Section	Class	Group
A	A61	A61K39/215
A	A61	A61K39/39
C	C12	C12N15/86
A	A61	A61K2039/545
A	A61	A61K2039/55505
A	A61	A61P31/14
C	C12	C12N2710/10343
C	C12	C12N2770/20022
C	C12	C12N2770/20034

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Vaccine development, immunology, and biotechnology, specifically focusing on coronavirus vaccine design and delivery technologies. Requires advanced knowledge of molecular biology, virology, immunological engineering, and vaccine formulation strategies

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with a PhD in virology, immunology, or molecular biology, having expertise in vaccine design, antigen engineering, viral vector technologies, and experience with adenovirus-based vaccine platforms

Obviousness Rationale

A PHOSITA would recognize that integrating advanced monitoring and diagnostic technologies with an existing adenovirus-based SARS-CoV-2 vaccine represents a natural progression of vaccine development strategies. The combination of AI, blockchain, and IoT technologies with established vaccine platforms provides predictable enhancements to vaccine efficacy, distribution tracking, and patient monitoring. These technological integrations represent incremental improvements that would be obvious to a skilled practitioner seeking to optimize vaccine deployment and effectiveness.

Obvious Combinations & Variations

Source Patent Element

Replication-defective adenovirus encoding SARS-CoV-2 spike and nucleocapsid proteins

PTD Variation

Adding AI-powered diagnostic tools for infection detection alongside the adenovirus vaccine

Obviousness Reasoning

Integrating diagnostic technologies with vaccine platforms is a known technique for enhancing disease management, representing a predictable combination of existing technologies

Source Patent Element

Intranasal and injectable vaccine delivery methods

PTD Variation

Incorporating blockchain tracking for vaccine distribution and administration

Obviousness Reasoning

Implementing supply chain and administration tracking is a standard approach in vaccine development, representing a design choice with predictable implementation strategies

Source Patent Element

Vaccine composition with nucleocapsid and spike protein sequences

PTD Variation

Optimizing protein sequences for enhanced cell surface expression using machine learning algorithms

Obviousness Reasoning

Computational optimization of protein sequences is a well-established technique in protein engineering, representing a finite set of known approaches for improving antigen presentation

Source Patent Element

Vaccine delivery using replication-defective adenovirus

PTD Variation

Adding IoT-enabled sensors for antigen detection in bodily fluids

Obviousness Reasoning

Incorporating real-time monitoring technologies into medical interventions is a predictable extension of existing diagnostic and tracking methodologies

Source Patent Element

Basic vaccine composition with nucleocapsid and spike proteins

PTD Variation

Formulating vaccine with novel materials having enhanced immunogenic properties

Obviousness Reasoning

Material science optimization is a standard approach in vaccine development, representing an obvious improvement strategy known to those skilled in the art

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857620 and the disclosed technological variations, a person having ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The combination of adenovirus-based vaccine technologies with AI, blockchain, IoT, and novel material formulations represents predictable variations that would be readily conceived by a skilled practitioner seeking to enhance vaccine efficacy, distribution, and monitoring capabilities.

Original Patent Information

Patent Number	US 11,857,620
Title	Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
Assignee(s)	ImmunityBio, Inc.